A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation

James L. Gajewski, Viviana V. Johnson, S. Gerald Sandler, Antoine Sayegh, Thomas R. Klumpp

    Research output: Contribution to journalArticle

    59 Citations (Scopus)

    Abstract

    The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.

    Original languageEnglish (US)
    Pages (from-to)3036-3047
    Number of pages12
    JournalBlood
    Volume112
    Issue number8
    DOIs
    StatePublished - Oct 15 2008

    Fingerprint

    Cell Transplantation
    Hematopoietic Stem Cells
    Blood
    Transplantation
    Transplantation (surgical)
    HLA Antigens
    Medicine
    Communication
    Transfusion Medicine
    Physicians
    Blood Transfusion
    Immunosuppression
    Referral and Consultation
    Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate

    ASJC Scopus subject areas

    • Hematology
    • Biochemistry
    • Cell Biology
    • Immunology

    Cite this

    Gajewski, J. L., Johnson, V. V., Sandler, S. G., Sayegh, A., & Klumpp, T. R. (2008). A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood, 112(8), 3036-3047. https://doi.org/10.1182/blood-2007-10-118372

    A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. / Gajewski, James L.; Johnson, Viviana V.; Sandler, S. Gerald; Sayegh, Antoine; Klumpp, Thomas R.

    In: Blood, Vol. 112, No. 8, 15.10.2008, p. 3036-3047.

    Research output: Contribution to journalArticle

    Gajewski, JL, Johnson, VV, Sandler, SG, Sayegh, A & Klumpp, TR 2008, 'A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation', Blood, vol. 112, no. 8, pp. 3036-3047. https://doi.org/10.1182/blood-2007-10-118372
    Gajewski, James L. ; Johnson, Viviana V. ; Sandler, S. Gerald ; Sayegh, Antoine ; Klumpp, Thomas R. / A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. In: Blood. 2008 ; Vol. 112, No. 8. pp. 3036-3047.
    @article{0730cae41b474e1fb4a0673495a38bc6,
    title = "A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation",
    abstract = "The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.",
    author = "Gajewski, {James L.} and Johnson, {Viviana V.} and Sandler, {S. Gerald} and Antoine Sayegh and Klumpp, {Thomas R.}",
    year = "2008",
    month = "10",
    day = "15",
    doi = "10.1182/blood-2007-10-118372",
    language = "English (US)",
    volume = "112",
    pages = "3036--3047",
    journal = "Blood",
    issn = "0006-4971",
    publisher = "American Society of Hematology",
    number = "8",

    }

    TY - JOUR

    T1 - A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation

    AU - Gajewski, James L.

    AU - Johnson, Viviana V.

    AU - Sandler, S. Gerald

    AU - Sayegh, Antoine

    AU - Klumpp, Thomas R.

    PY - 2008/10/15

    Y1 - 2008/10/15

    N2 - The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.

    AB - The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.

    UR - http://www.scopus.com/inward/record.url?scp=54049156146&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=54049156146&partnerID=8YFLogxK

    U2 - 10.1182/blood-2007-10-118372

    DO - 10.1182/blood-2007-10-118372

    M3 - Article

    C2 - 18583566

    AN - SCOPUS:54049156146

    VL - 112

    SP - 3036

    EP - 3047

    JO - Blood

    JF - Blood

    SN - 0006-4971

    IS - 8

    ER -